Study S001236

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02773368
Acronym: DUALTM IX
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 420
Start: 2016-05-23
Primary completion: 2017-09-26
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:insulin degludec/liraglutide; DRUG:insulin glargine
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2015-001596-48; OTHER:U1111-1168-9343; OTHER:REec-2016-2248; NIH:2015

Registered primary outcomes

Change in HbA1c (Glycosylated Haemoglobin) [Week 0, Week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014323	Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Philis-Tsimikas A, Diabetes, obesity & metabolism	2019	Randomized trial	PMID 30761720 DOI	registry reference RESULT:30761720